Cargando…
Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications
BACKGROUND: Tuberous sclerosis (TSC) is a monogenic disease resulting from defects of the TSC1 or TSC2 genes, which encode the proteins forming hamartin-tuberin tumor suppressor complex, the mammalian target of rapamycin complex (mTOR). The mTOR pathway is constitutively activated in response to tub...
Autores principales: | Trelinska, Joanna, Fendler, Wojciech, Dachowska, Iwona, Kotulska, Katarzyna, Jozwiak, Sergiusz, Antosik, Karolina, Gnys, Piotr, Borowiec, Maciej, Mlynarski, Wojciech |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041396/ https://www.ncbi.nlm.nih.gov/pubmed/27680012 http://dx.doi.org/10.1186/s13023-016-0512-1 |
Ejemplares similares
-
Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis – Final Results From the EMINENTS Study
por: Bobeff, Katarzyna, et al.
Publicado: (2021) -
mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile
por: Pawlik, Bartłomiej, et al.
Publicado: (2022) -
Central Nervous System PET-CT Imaging Reveals Regional Impairments in Pediatric Patients with Wolfram Syndrome
por: Zmyslowska, Agnieszka, et al.
Publicado: (2014) -
Single patient in GCK-MODY family successfully re-diagnosed into GCK-PNDM through targeted next-generation sequencing technology
por: Antosik, Karolina, et al.
Publicado: (2015) -
MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor
por: Pawlik, Bartłomiej, et al.
Publicado: (2022)